Dr Reddy's, Russian Firm Begin Clinical Trials For Covid Vaccine In India© timesofindia.indiatimes.com

Dr Reddy's, Russian Firm Begin Clinical Trials For Covid Vaccine In India

, 11 news, a view

New Delhi: Phase 2 and 3 clinical trials for the Russian COVID-19 vaccine Sputnik V commenced in India on Tuesday. Russian Direct Investment Fund (RDIF) and Dr Reddy’s Laboratories on Tuesday announced that they have commenced adaptive Phase 2 and 3 clinical trials for the coronavirus vaccine. Also Read - RDIF, Hetero Agree to Produce Over 100 Million Doses of Sputnik V Vaccine in India

The Sputnik V vaccine is based on a well-studied human adenoviral vector platform that had proven safe and effective with no long-term side effects in more than 250 clinical trials globally conducted during the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953). More than 100,000 people have received approved and registered drugs based on the human adenoviral vectors. Also Read - Russia's Sputnik V To Cost Lower Than Pfizer, Moderna's COVID Vax

Last month, Russia said that its vaccine Sputnik V is 92 per cent effective at protecting people from COVID-19, according to the first interim analysis.